Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy

Hepatology Research

Volumn 45, Issue 2, 2015, Pages 152-161

  Hiramatsu, Naoki ^a   Oze, Tsugiko ^a   Takehara, Tetsuo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Interferon therapy; Sustained virological response

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; GLUCOSE; INTERFERON;

AGE; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; CANCER INCIDENCE; GENDER; GLUCOSE METABOLISM; HEPATITIS C; HUMAN; LIPID METABOLISM; LIVER CELL CARCINOMA; LIVER FIBROSIS; METABOLIC DISORDER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT RESPONSE;

EID: 84921458572     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12393     Document Type: Review

References (41)

1. Ikeda K, Saitoh S, Arase Y etal. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1, 643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29: 1124-1130.
2. Kasahara A, Hayashi N, Mochizuki K etal. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-1402.
3. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181.
4. Imai Y, Kawata S, Tamura S etal. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129: 94-99.
5. Okanoue T, Itoh Y, Minami M etal. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30: 653-659.
6. Serfaty L, Aumaitre H, Chazouilleres O etal. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-1440.
7. Shiratori Y, Ito Y, Yokosuka O etal. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-114.
8. Gramenzi A, Andreone P, Fiorino S etal. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001; 48: 843-848.
9. Bruno S, Stroffolini T, Colombo M etal. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
10. Nishiguchi S, Shiomi S, Nakatani S etal. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001; 357: 196-197.
11. Bruno S, Silini E, Crosignani A etal. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 754-758.
12. Hamada H, Yatsuhashi H, Yano K etal. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002; 95: 331-339.
13. Kurokawa M, Hiramatsu N, Oze T etal. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res 2009; 39: 432-438.
14. Ogawa E, Furusyo N, Kajiwara E etal. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013; 58: 495-501.
15. Watanabe S, Enomoto N, Koike K etal. Cancer preventive effect of pegylated interferon alpha-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis. Hepatol Res 2011; 41: 955-964.
16. Cardoso AC, Moucari R, Figueiredo-Mendes C etal. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-657.
17. Oze T, Hiramatsu N, Yakushijin T etal. Post-treatment levels of alpha-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 2014; 12: 1186-1195.
18. Hung CH, Lee CM, Wang JH etal. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer 2011; 128: 2344-2352.
19. Tateyama M, Yatsuhashi H, Taura N etal. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol 2011; 46: 92-100.
20. Arase Y, Kobayashi M, Suzuki F etal. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57: 964-973.
21. Kawamura Y, Arase Y, Ikeda K etal. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med 2010; 123: 951-956 e1.
22. Asahina Y, Tsuchiya K, Tamaki N etal. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518-527.
23. Ikeda K, Arase Y, Saitoh S etal. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-232.
24. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17: 287-292.
25. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010; 52: 889-894.
26. Tanimoto Y, Tashiro H, Aikata H etal. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol 2012; 19: 418-425.
27. Hagihara H, Nouso K, Kobayashi Y etal. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 2011; 16: 210-220.
28. Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology 2013; 58: 150-157.
29. Ikeda M, Fujiyama S, Tanaka M etal. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol 2005; 40: 148-156.
30. Tokita H, Fukui H, Tanaka A etal. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol 2005; 20: 752-758.
31. Asahina Y, Tsuchiya K, Nishimura T etal. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58: 1253-1262.
32. Aleman S, Rahbin N, Weiland O etal. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57: 230-236.
33. Morgan TR, Ghany MG, Kim HY etal. HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-844.
34. Makiyama A, Itoh Y, Kasahara A etal. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004; 101: 1616-1622.
35. Tanaka A, Uegaki S, Kurihara H etal. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007; 13: 5180-5187.
36. Akuta N, Suzuki F, Hirakawa M etal. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy. J Med Virol 2011; 83: 1016-1022.
37. Toyoda H, Kumada T, Tokuda A etal. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J Viral Hepat 2000; 7: 414-419.
38. Ikeda M, Fujiyama S, Tanaka M etal. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C. J Gastroenterol Hepatol 2006; 21: 122-128.
39. Hirakawa M, Ikeda K, Arase Y etal. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med 2008; 47: 1637-1643.
40. Nagaoki Y, Aikata H, Miyaki D etal. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. J Gastroenterol 2011; 46: 799-808.
41. Sato A, Sata M, Ikeda K etal. Clinical characteristics of patients who developed hepatocellular carcinoma after hepatitis C virus eradication with interferon therapy: current status in Japan. Intern Med 2013; 52: 2701-2706.